Drug Trial Radar · NCT03498521
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
529
Actual
Start
Jul 10, 2018
Primary completion
Feb 14, 2023
Study completion Nov 7, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Foundation Medicine
- First posted
- Apr 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.
Conditions
- Cancer of Unknown Primary Site
Interventions
AlectinibDrug
Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
VismodegibDrug
Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
IpatasertibDrug
Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
OlaparibDrug
Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
ErlotinibDrug
Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
BevacizumabDrug
Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
VemurafenibDrug
Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
CobimetinibDrug
Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Trastuzumab Subcutaneous (SC)Drug
Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
PertuzumabDrug
Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
AtezolizumabDrug
Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
CarboplatinDrug
Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
PaclitaxelDrug
Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
CisplatinDrug
Cisplatin will be administered intravenously, 60-75 mg/m\^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
GemcitabineDrug
Gemcitabine will be administered intravenously, 1000 mg/m\^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
EntrectinibDrug
Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
IvosidenibDrug
Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
PemigatinibDrug
Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)Time frame: From randomization to the first occurrence of disease progression or death from any cause, until 330 PFS events were observed (approx. 4.3 years for MGT Cat 1 and 3.4 years for Chemotherapy Cat 1).
Locations
125 sites in 33 countries. Site status is shown where the registry gives one.
Blacktown Hospital
Blacktown, New South Wales, Australia
GenesisCare North Shore
St Leonards, New South Wales, Australia
Icon Cancer Foundation
South Brisbane, Queensland, Australia
Lkh-Univ. Klinikum Graz
Graz, Austria
Lkh Salzburg - Univ. Klinikum Salzburg
Salzburg, Austria
Medizinische Universität Wien
Vienna, Austria
Instituto Nacional de Cancer - INCa
Rio de Janeiro, Brazil
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
MHAT Nadezhda
Sofia, Bulgaria
MBAL Serdika EOOD
Sofia, Bulgaria
Bradford Hill Centro de Investigaciones Clinicas
Recoleta, Chile
James Lind Centro de Investigación Del Cáncer
Temuco, Chile
Clinica del Country
Bogotá, Colombia
Inst. Nacional de Cancerologia
Bogotá, Colombia
Oncomedica S.A.
Montería, Colombia
Clinical Hospital Centre Zagreb
Zagreb, Croatia
Masarykuv onkologicky ustav
Brno, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
Fakultni Poliklinika Vseobecne Fakultni Niemocnice
Prague, Czechia
Aarhus Universitetshospital
Aarhus N, Denmark
North Estonia Medical Centre, Oncology and hematology Clinic
Tallinn, Estonia
Helsinki University Central Hospital
Helsinki, Finland
Tampere University Hospital
Tampere, Finland
Ico - Paul Papin
Angers, France
CHRU Besançon
Besançon, France
Institut Bergonie
Bordeaux, France
CRLCC-Francois Baclesse
Caen, France
Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne
Clermont-Ferrand, France
Centre Leon Berard
Lyon, France
Institut Paoli-Calmettes
Marseille, France
Institut régional du Cancer Montpellier
Montpellier, France
Centre Antoine Lacassagne
Nice, France
Institut Curie
Paris, France
CHU Lyon - Centre Hospitalier Lyon Sud
Pierre-Benite (Lyon), France
Centre Eugene Marquis
Rennes, France
CHU Strasbourg Hpital Hautepierre
Strasbourg, France
Hopital Foch
Suresnes, France
Showing 40 of 125 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.